![Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy](https://www.facingourrisk.org/cdn-cgi/image/width=400,height=300,fit=contain,format=webp/uploads/assets/research/images/6371b29314c21.jpg)
Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy
Clinicaltrials.gov identifier:
NCT04455750
Treatment study for men with metastatic prostate cancer
Study Contact Information:
For additional information, please contact:
Arpit Rao, MD 713-798-4508 [email protected]
Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy
About this Study
This study is testing the effectiveness of adding a type of known as a to androgen-deprivation therapy for men with prostate cancer that has become resistant to standard . NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.
NOTE: This study is no longer enrolling people.